U.S. Insurance Stock News

Becton Dickinson reported strong fiscal third quarter results earlier this month, with both organic revenue growth and earnings per share exceeding market expectations. These results spurred heightened interest from analysts, highlighting continued momentum in the company’s core diagnostics and medical devices businesses. We'll now consider how Becton Dickinson's robust quarterly performance may influence its investment narrative and long-term growth expectations. Find companies with...

FactSet Research Systems (FDS) Piques Investor Curiosity Amid New Product Integrations and Earnings Buzz If you follow FactSet Research Systems (FDS), recent headlines have offered plenty to chew on. The company just rolled out an exclusive integration of MarketAxess’ AI-powered bond pricing data directly into its Workstation platform, targeting the core of institutional trading workflows. In addition, FactSet announced a partnership with Hebbia to further enhance data accessibility for its...

Wondering what to do with Evolent Health stock after a wild ride in the market? You are not alone. The stock has turned heads in both directions lately, with a 6.7% dip over the past week and a 3% slip over the past month. If you have held on through the past year, it has been especially challenging, given a staggering 70.3% drop over that period. Even the longer-term returns, down 76.4% for three years and 21.6% over five years, may have shaken the confidence of even the most steadfast...

Agilysys (AGYS) just scored a major client win that is turning heads across the hospitality tech world. The company announced that the Saskatchewan Indian Gaming Authority (SIGA) will roll out Agilysys InfoGenesis POS along with its Eatec inventory solutions throughout all seven of SIGA’s casino properties. This is not just another logo; deployment at enterprise scale like this is real-world validation of Agilysys’s ability to centralize key operations and support digital transformation for...

If you’re watching Rayonier (RYN) and wondering what’s behind its recent moves, you’re not alone. There hasn’t been any splashy event or headline. Sometimes a stretch of calm can actually prompt investors to look closer, especially with a stock that’s seen its share of ups and downs. The steady price action might not spark headlines, yet it can raise questions about how the market is currently viewing Rayonier’s prospects. Looking back at the past year, Rayonier’s performance has been mixed...

ExlService Holdings (EXLS) just made headlines by announcing a strategic partnership with InsureMO, a move that directly targets the urgent need for modernization in the insurance industry. This collaboration is set to provide insurers with faster, more flexible solutions for updating core systems, integrating AI, and accelerating their digital transformation journeys. By combining EXLS’s deep insurance expertise and AI know-how with InsureMO’s cloud-native middleware, the joint effort...

Thinking about Albemarle for your portfolio right now? You are not alone. Whether you are considering holding, buying, or just watching from the sidelines, Albemarle has been on a remarkable ride that is capturing plenty of attention and debate. The stock price has slipped sharply, down 7.3% in the last week and 7.6% over the past month. Widen the lens and you will see Albemarle is down 13.1% from a year ago, tumbling an eye-opening 73.3% over three years. Even the five-year return is...

On September 8, 2025, Marqeta announced the appointment of Mike Milotich as its permanent Chief Executive Officer and new Board member, while also reporting second-quarter revenues that surpassed analysts’ expectations and showed a year-on-year increase of 20.1%. Despite these operational highlights, management issued a cautious outlook regarding future profitability due to anticipated headwinds from upcoming major contract renewals expected to impact gross profit growth starting in late...

If you’re following Precigen (PGEN), you know it’s not every day a biotech firm captures Wall Street’s attention like this. The spark? Precigen recently scored FDA approval for Papzimeos, its therapy for adults with recurrent respiratory papillomatosis. This is the first approved treatment for a condition that previously had few good options, setting the stage for both a clinical impact and a new revenue stream. The FDA greenlight sent Precigen’s stock surging over 300% year-to-date, an...

Constellation Energy (CEG) is back in the spotlight after a combination of significant news: a strategic partnership with Meta to safeguard the future of its Clinton Clean Energy Center, and a leadership shakeup as Chris Mudrick steps in as chief nuclear officer. For investors weighing their next move, these developments are not just headlines; they might be signals of how the company plans to lead in the next era of energy and data-driven growth. The Meta deal underscores the growing demand...

If you caught yourself glancing at STAG Industrial (STAG) recently and wondered if the stock’s recent moves are a sign of something deeper, you’re not alone. There hasn’t been a headline-grabbing event propelling shares one way or another, but that in itself raises an interesting question. When a real estate stock with a broad tenant base meanders quietly against a turbulent market backdrop, it’s natural to wonder if the price action is simply business as usual or if subtle shifts are at...

In the past week, Universal Technical Institute experienced active trading following softer-than-expected US inflation data, which shifted market focus toward potential interest rate cuts by the Federal Reserve. This market response highlights how education service providers like Universal Technical Institute can be sensitive to broader monetary policy shifts that affect affordability and enrollment trends. We'll explore how renewed investor optimism about easier Fed policy may influence...

MasTec (MTZ) is suddenly in the spotlight after a sharp drop in the Producer Price Index for August ignited a rally across the industrial sector. With inflation easing, investors are betting on a Federal Reserve interest rate cut as soon as the next meeting. For MasTec, which already signaled openness to new acquisitions in recent comments from CFO Paul DiMarco, lower borrowing costs could provide more flexibility for strategic investment and expansion. This latest wave of optimism comes on...

Fiserv (FI) is at the center of a surge in investor attention after class action lawsuits alleged the company misled the market about growth in its Clover platform. The lawsuits claim Fiserv temporarily boosted its numbers by moving merchants from the older Payeezy system to Clover, concealing a slowdown in new client business. With disclosures surfacing about merchants leaving due to higher prices and service challenges, investors are now sifting through the company’s recent narrative to...

CorMedix (CRMD) has been catching some fresh attention lately, and it is fair to wonder if something is brewing beneath the surface. While there have not been headline-grabbing developments this month, the number of investors watching the stock tick up or down may be a signal in itself, especially for anyone wondering about where the valuation stands. Looking at the big picture, CorMedix has had an eventful twelve months, with the share price rising over 83% for the year. That move sits...

Earlier this month, Domino's Pizza Inc. expanded its menu by introducing Cinnamon and Garlic Bread Bites, joining Parmesan Bread Bites and offering them as part of its Mix & Match Deal, where customers select two or more items for US$6.99 each. This menu innovation coincides with stronger U.S. restaurant spending and may help Domino's attract more customers seeking value and variety. We'll examine how these Bread Bite additions and enhanced value offerings could influence Domino's investment...

Earlier this month, Exact Sciences introduced Cancerguard™, a multi-cancer early detection blood test, entering direct competition with NeoGenomics in the oncology diagnostics market. This development follows NeoGenomics' recent legal win enabling broader commercialization of its RaDaR® ST assay, highlighting the rapidly intensifying competition in the multi-cancer testing segment. We'll explore how the emergence of a major new competitor in early cancer detection may impact NeoGenomics'...

Recently, Taylor Morrison Home Corporation drew attention for trading below the industry average price-to-earnings ratio at a time of expected earnings declines and, in the past, marked progress nearing completion of 148 rental homes at its Yardly City Park project in Charlotte. This combination of potentially attractive valuation and ongoing expansion in the rental sector underscores the contrast between operational progress and anticipated financial headwinds. We'll examine how concerns...

American Homes 4 Rent (AMH) has turned some heads lately. If you’re a shareholder or considering a move into the stock, you're right to wonder what’s happening beneath the surface. There isn’t a single big headline driving the action this week, but the recent drip in price may have many investors double-checking their positions or looking for clues on what the next catalyst might be. With AMH, sometimes even quiet stretches create valuable opportunities if you know where to look. Zooming...

Earlier this week, Camtek completed a US$425 million private offering of zero coupon convertible senior notes due 2030, with proceeds primarily allocated to repurchase part of its 2026 convertible notes and fund general corporate purposes such as acquisitions and R&D. This move extends Camtek's debt maturity profile and signals the company's intent to invest further in growth opportunities while managing financial flexibility and dilution risk. We'll explore how Camtek's upsized convertible...

If you’ve been watching Wendy's (WEN) lately, you’ve probably noticed it is caught up in a storm of skepticism. The company is wrestling with stagnant sales and softer earnings expectations, set against a backdrop where consumers increasingly want healthier and more convenient choices. In addition, the wave of analyst downgrades has left investors questioning whether Wendy’s can reinvent itself or if the market is bracing for lingering challenges. Recent months have been bumpy for Wendy's...

If you’re keeping an eye on CRH (NYSE:CRH), the latest sequence of moves may have you rethinking your next step. The company has just announced a hefty share buyback program aiming to purchase as much as $300 million in stock by November 2025. In addition, CRH named Patrick Decker, an executive with a track record in industrial and water technology leadership, to its Board of Directors. Both actions indicate a focus on shareholder value and corporate oversight, leaving investors to consider...

If you are weighing your options with Indivior, you are not alone in wondering whether now is the right time to get on board, hold steady, or lock in some gains. Indivior has made plenty of headlines with its impressive long-term performance. The stock has soared 143.3% over the past year and a staggering 211.5% over five years, turning patient investors into clear winners. Even so, the past month shows a mild pullback of -1.1%, and the last week has seen a sharper dip of -6.2%. These recent...

Key Insights Veralto's estimated fair value is US$135 based on 2 Stage Free Cash Flow to Equity Veralto's US$109 share...